Mohammad Aminur Rahman
Overview
Explore the profile of Mohammad Aminur Rahman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
611
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haque A, Rahman M, Fuchs J, Chen Z, Khuri F, Shin D, et al.
Cancer Lett
. 2020 Oct;
498:249-250.
PMID: 33092912
No abstract available.
2.
Wang D, Muller S, Amin A, Huang D, Su L, Hu Z, et al.
Clin Cancer Res
. 2020 Sep;
26(18):5052.
PMID: 32934033
No abstract available.
3.
Md Anisuzzaman A, Haque A, Wang D, Rahman M, Zhang C, Chen Z, et al.
Mol Cancer Ther
. 2020 Sep;
19(9):1955.
PMID: 32879030
No abstract available.
4.
Rahman M, Wang P, Zhao Z, Wang D, Nannapaneni S, Zhang C, et al.
Angew Chem Int Ed Engl
. 2020 Jul;
59(31):12575.
PMID: 32691956
No abstract available.
5.
Wang P, Rahman M, Zhao Z, Weiss K, Zhang C, Chen Z, et al.
J Am Chem Soc
. 2018 Feb;
140(7):2478-2484.
PMID: 29406750
DNA origami is a promising molecular delivery system for a variety of therapeutic applications including cancer therapy, given its capability to fabricate homogeneous nanostructures whose physicochemical properties (size, shape, surface...
6.
Rahman M, Wang P, Zhao Z, Wang D, Nannapaneni S, Zhang C, et al.
Angew Chem Int Ed Engl
. 2017 Oct;
56(50):16023-16027.
PMID: 29076273
Short interfering RNA (siRNA) is a promising molecular tool for cancer therapy, but its clinical success is limited by the lack of robust in vivo delivery systems. Rationally designed DNA...
7.
Zhang J, Nannapaneni S, Wang D, Liu F, Wang X, Jin R, et al.
Oncotarget
. 2017 Sep;
8(35):59008-59022.
PMID: 28938614
MEK inhibition is potentially valuable in targeting KRAS-mutant non-small cell lung cancer (NSCLC). Here, we analyzed whether concomitant LKB1 mutation alters sensitivity to the MEK inhibitor selumetinib, and whether the...
8.
Ali M, Rahman M, Wu Y, Han T, Peng X, Mackey M, et al.
Proc Natl Acad Sci U S A
. 2017 Mar;
114(15):E3110-E3118.
PMID: 28356516
Gold nanorods (AuNRs)-assisted plasmonic photothermal therapy (AuNRs-PPTT) is a promising strategy for combating cancer in which AuNRs absorb near-infrared light and convert it into heat, causing cell death mainly by...
9.
Md Anisuzzaman A, Haque A, Wang D, Rahman M, Zhang C, Chen Z, et al.
Mol Cancer Ther
. 2017 Jan;
16(4):729-738.
PMID: 28119490
We previously reported that the EGFR-targeted inhibitor erlotinib induces G arrest of squamous cell carcinoma of the head and neck (SCCHN) cell lines without inducing significant apoptosis. Large-scale genomic studies...
10.
Zhao Z, Rahman M, Chen Z, Shin D
Oncotarget
. 2017 Jan;
8(12):20380-20393.
PMID: 28099910
Twist1 is a well-known regulator of transcription during embryonic organogenesis in many species. In humans, Twist1 malfunction was first linked to Saethre-Chotzen syndrome and later identified to play an essential...